AbbVie Reports Third-Quarter 2024 Financial Results - PR Newswire

Oct 30, 2024 · Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These...

CouponFollow Extension

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results - PR Newswire

1 week from now

Oct 30, 2024 · Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These...

prnewswire.com

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

NORTH CHICAGO, Ill., Oct. 30, 2024. Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; …

morningstar.com

$0.88
OFF

Abbvie News & Press Releases - PR Newswire

1 week from now

Oct 30, 2024, 07:38 ET AbbVie Reports Third-Quarter 2024 Financial Results Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted …

prnewswire.com

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

Oct 30, 2024 · The MarketWatch News Department was not involved in the creation of this content. NORTH CHICAGO, Ill., Oct. 30, 2024. -- Reports Third-Quarter Diluted EPS of $0.88 …

marketwatch.com

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results - Nasdaq

1 week from now

Published. Oct 30, 2024 7:38am EDT. Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; …

nasdaq.com

0%
OFF

AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

Oct 30, 2024 · Financial Highlights. AbbVie reported third-quarter diluted earnings per share (EPS) of $0.88 on a GAAP basis, a decrease of 12.0% compared to the same period last year. …

tradingview.com

$0.88
OFF

ABBV - AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

Oct 30, 2024 · AbbVie Reports Third-Quarter 2024 Financial Results PR Newswire Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis a Decrease of 12.0.

marketwirenews.com

$0.77
OFF

AbbVie Reports First-Quarter 2024 Financial Results - Yahoo Finance

1 week from now

Apr 26, 2024 · Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an …

yahoo.com

11%
OFF

Abbvie Inc (ABBV): ABBV—(-11%)—reports Phase-2 Failures_of...

1 week from now

Nov 11, 2024 · us tech 100. 20,590.40 ( 0.36% )

advfn.com

$10.86
OFF

AbbVie Reports Third-Quarter 2023 Financial Results - PR Newswire

1 week from now

Oct 27, 2023 · Full-Year 2023 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2023 from $10.86 - $11.06 to $11.19 - $11.23, which includes an unfavorable impact …

prnewswire.com

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results | AbbVie

1 week from now

Oct 30, 2024 · Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an …

abbvie.com

30%
OFF

BioLife Solutions Reports Third Quarter 2024 Financial Results

1 week from now

5 days ago · REVENUE. Total revenue for the third quarter of 2024 was $30.6 million, an increase of $7.0 million, or 30%, from $23.6 million for the third quarter of 2023 and up $2.2 million, or …

prnewswire.com

$87
OFF

Regulus Therapeutics Reports Third Quarter 2024 Financial Results …

1 week from now

Nov 7, 2024 · Financial Results. Cash, Cash Equivalents and Marketable Securities: As of September 30, 2024, Regulus had $87.3 million in cash, cash equivalents and short-term …

morningstar.com

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

Oct 30, 2024 · Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; ...

healthstockshub.com

$17
OFF

Protalix BioTherapeutics Reports Third Quarter 2024 Financial And ...

1 week from now

3 days ago · Third Quarter 2024 Financial Highlights. The Company recorded revenues from selling goods of $17.8 million during the three months ended September 30, 2024, an increase …

prnewswire.com

$14.46
OFF

AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

Third-Quarter Results. Worldwide net revenues were $14.460 billion, an increase of 3.8 percent on a reported basis, or 4.9 percent on an operational basis.; Global net revenues from the …

streetinsider.com

$17
OFF

Aileron Therapeutics Reports Third Quarter 2024 Financial Results …

1 week from now

3 days ago · Third Quarter 2024 Financial Results. Cash Position: Cash and cash equivalents as of September 30, 2024, were $17.7 million, compared to $21.9 million as of June 30, 2024. …

prnewswire.com

$0.77
OFF

AbbVie Reports Second-Quarter 2024 Financial Results | AbbVie

1 week from now

Jul 25, 2024 · Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results …

abbvie.com

$0.88
OFF

AbbVie Reports Third-Quarter 2024 Financial Results - GuruFocus

1 week from now

PR NewswireNORTH CHICAGO, Ill., Oct. 30, 2024 Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS

gurufocus.com

$77
OFF

Avidity Biosciences Reports Third Quarter 2024 Financial Results …

1 week from now

Nov 7, 2024 · These expenses were $77.2 million for the third quarter of 2024 compared with $47.7 million for the third quarter of 2023, and $208.0 million for the first nine months of 2024 …

prnewswire.com

$85
OFF

Novavax Reports Third Quarter 2024 Financial Results And …

1 week from now

5 days ago · Third Quarter 2024 Financial Results. Total revenue for the third quarter of 2024 was $85 million, compared to $187 million in the same period in 2023. Product sales of $38 million …

prnewswire.com

FAQs about AbbVie Reports Third-Quarter 2024 Financial Results - PR Newswire Coupon?

When will AbbVie announce its third-quarter 2024 financial results?

NORTH CHICAGO, Ill., Oct. 1, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) will announce its third-quarter 2024 financial results on Wednesday, October 30, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. ...

Will AbbVie participate in bank of America Securities healthcare conference 2024?

NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial officer, ...

What is included in AbbVie's 2024 adjusted diluted EPS guidance?

The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. ...

Does AbbVie make any changes to its forward-looking statements?

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024. ...

Why is AbbVie raising its diluted EPS guidance?

AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from , which includes an unfavorable impact of per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2024. ...

Will AbbVie participate in JP Morgan Healthcare Conference 2024?

NORTH CHICAGO, Ill. , Jan. 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 . Robert A. Michael , president and chief operating officer, Scott T. Reents , executive vice president, chief financial ...